Elizabeth Balta - 12 Feb 2026 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Reporting relationship: Chief Legal Officer and Corporate Secretary
Issuer ticker: JBIO
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 20:00:37 UTC
Prior SEC filing: 01 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Balta

Key filing fact

Elizabeth Balta filed Form 4 for Jade Biosciences, Inc. (JBIO) on 13 Feb 2026.

Key facts

This page summarizes Elizabeth Balta's Form 4 filing for Jade Biosciences, Inc. (JBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 20:00.

Change

Previous filing in this sequence was filed on 01 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884087 Primary reporting owner

Balta Elizabeth

Relationship: Chief Legal Officer and Corporate Secretary
Address: C/O JADE BIOSCIENCES, INC., 221 CRESCENT ST., BLDG. 23, STE. 105, WALTHAM
Signature: /s/ Elizabeth Balta
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JBIO transaction

Common Stock

Award

Transaction value: $0
Shares: +28,125
Change %
Price: $0.000000
Shares after: 28,125
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +168,750
Change %
Price: $0.000000
Shares after: 168,750
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 168,750
Exercise price: $14.81
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F2

This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

Chief Legal Officer and Corporate Secretary